review
focus
immun
anim
mean
prevent
human
diseas
zoonos
three
framework
use
vaccin
context
describ
exampl
provid
success
failur
framework
vaccin
use
protect
human
econom
valuabl
anim
neither
play
role
transmiss
cycl
benefit
collabor
anim
health
human
health
industri
regul
develop
product
discuss
one
exampl
west
nile
vaccin
singl
product
develop
use
anim
human
describ
framework
ii
vaccin
indic
domest
anim
mean
prevent
diseas
anim
human
agent
concern
transmit
directli
indirectli
eg
via
arthropod
vector
anim
human
number
exampl
use
framework
ii
vaccin
provid
eg
brucellosi
escherischia
coli
rabi
rift
valley
fever
venezuelan
equin
enceph
hendra
viru
framework
iii
vaccin
use
immun
wild
anim
mean
prevent
transmiss
diseas
agent
human
domest
anim
exampl
reservoirtarget
oral
bait
rabi
mycobacterium
bovi
lyme
diseas
vaccin
given
speed
lost
cost
veterinari
vaccin
develop
intervent
base
immun
anim
could
lead
rapid
rel
inexpens
advanc
public
health
opportun
vaccinebas
approach
prevent
zoonot
emerg
diseas
integr
veterinari
human
medicin
one
health
paradigm
emphas
zoonos
diseas
transmiss
anim
human
account
approxim
infecti
pathogen
human
be
emerg
infecti
diseas
origin
diseas
underli
factor
includ
manmad
factor
emerg
subject
consider
interest
certain
zoonot
diseas
potenti
pandem
spread
human
contagion
avian
influenza
sar
middl
east
respiratori
syndrom
coronaviru
other
region
crossbord
epizoot
yellow
fever
venezuelan
equin
enceph
rift
valley
fever
cost
short
list
zoonot
diseas
emerg
interv
includ
bovin
spongiform
encephalopathi
sar
highli
pathogen
avian
influenza
west
nile
pneumon
plagu
india
estim
exceed
billion
major
emerg
concern
public
health
includ
hurrican
earthquak
terrorist
attack
occur
zoonot
diseas
outbreak
howev
toll
public
health
much
greater
caus
dramat
outbreak
estim
differ
zoonot
diseas
respons
annual
billion
case
human
diseas
million
death
substanti
reduct
livestock
product
anim
includ
livestock
companion
anim
also
suffer
ill
death
follow
infect
mani
zoonot
infect
livestock
poultri
subject
largescal
intent
destruct
mean
prevent
human
infect
result
huge
econom
loss
wild
anim
includ
endang
speci
may
also
mortal
affect
exampl
west
nile
diseas
bird
yellow
fever
neotrop
monkey
plagu
blackfoot
ferret
ebola
great
ape
vaccin
import
mean
prevent
control
zoonot
infecti
diseas
human
domest
anim
howev
target
vaccin
almost
case
directli
affect
speci
practic
implement
illustr
potenti
indirectli
prevent
human
diseas
immun
domest
companion
anim
sourc
infect
concept
immun
wild
anim
reservoir
prevent
diseas
human
domest
anim
even
challeng
receiv
limit
attent
moreov
human
anim
health
divis
biopharmaceut
industri
gener
separ
segreg
organ
approach
develop
new
vaccin
indic
prevent
spread
diseas
domest
wild
anim
human
addit
major
fund
sourc
research
human
anim
diseas
tend
stovepip
differ
govern
agenc
stifl
crosscut
approach
purpos
review
stimul
scienc
polici
commun
seek
innov
way
interdict
zoonot
diseas
integr
human
veterinari
medicin
vaccin
develop
creat
new
stream
fund
aim
intersect
human
anim
health
aim
consist
one
health
initi
seek
establish
collabor
effort
multipl
disciplin
work
local
nation
global
attain
optim
health
peopl
anim
environ
framework
consid
one
health
vaccin
intervent
provid
well
brief
review
past
current
effort
includ
success
obviou
reader
wideopen
field
mani
opportun
deserv
attent
receiv
complex
timelin
cost
develop
anim
vaccin
regulatori
hurdl
product
approv
far
less
human
vaccin
thu
intervent
base
immun
anim
could
lead
rapid
rel
inexpens
advanc
public
health
obviou
benefit
human
health
deriv
vaccin
anim
far
easier
justifi
also
benefit
anim
health
latter
often
close
link
econom
valu
caus
agent
zoonot
diseas
includ
virus
parasit
bacteria
fungi
prion
extraordinarili
vari
life
cycl
mode
transmiss
may
persist
period
activ
transmiss
soil
invertebr
speci
mani
silent
transmiss
cycl
involv
wild
anim
coevolv
infecti
agent
exhibit
sign
diseas
zoonot
diseas
occur
caus
agent
harbor
wild
anim
reservoir
jump
speci
domest
anim
thenc
human
other
primarili
diseas
domest
anim
speci
human
may
infect
direct
contact
wild
domest
anim
indirectli
ingest
contamin
milk
meat
inhal
aerosol
secret
excreta
fomit
hematophag
insect
tick
vector
despit
complex
epidemiolog
pattern
opportun
intervent
often
boil
simpl
bottleneck
transmiss
process
exampl
milkborn
diseas
prevent
pasteur
certain
meatborn
diseas
inspect
anim
husbandri
improv
eg
trichinella
bovin
tuberculosi
diseas
avoid
limit
contact
known
high
risk
speci
eg
tularemia
turtleborn
salmonellosi
exposur
bat
carri
henipavirus
risk
infect
high
result
diseas
sever
vaccin
may
effici
costeffect
mean
prevent
control
altern
method
control
zoonot
diseas
gener
employ
trap
poison
mean
destroy
offend
anim
reservoirvector
method
mix
often
neg
record
success
case
becom
social
unaccept
review
focus
use
vaccin
anim
accept
mean
interdict
zoonot
diseas
anim
human
three
major
epidemiolog
framework
identifi
control
zoonot
diseas
mean
vaccin
anim
tabl
scope
review
encompass
diseas
strategi
target
vaccin
anim
actual
use
develop
mani
diseas
tabl
framework
vaccin
develop
util
mean
prevent
zoonot
diseas
statu
approv
exist
vaccin
human
anim
first
major
framework
includ
zoonot
infecti
diseas
affect
human
econom
import
anim
wild
anim
sourc
infect
livestock
human
deadend
host
neither
contribut
transmiss
cycl
case
vaccin
requir
prevent
diseas
human
econom
import
anim
interrupt
transmiss
diseas
natur
framework
diseas
import
opportun
acceler
develop
new
vaccin
concurr
veterinari
human
product
research
tabl
moreov
affect
anim
speci
repres
natur
diseas
model
infect
pathogenesi
immun
may
use
test
efficaci
immunolog
correl
protect
new
vaccin
intend
human
use
thu
provid
data
support
regulatori
approv
fda
anim
rule
list
framework
diseas
vaccin
shown
tabl
exampl
given
west
nile
viru
mosquitoborn
singl
strand
positivesens
envelop
rna
viru
genu
flaviviru
famili
flavivirida
close
relat
japanes
enceph
viru
west
nile
viru
recogn
caus
human
diseas
rang
mild
feverrashheadach
syndrom
lethal
encephalomyel
hors
domest
gees
farm
allig
well
number
wild
bird
mammal
also
suscept
sever
fatal
diseas
although
recogn
caus
diseas
earli
west
nile
becam
increas
problem
outbreak
affect
human
andor
hors
northern
africa
western
europ
eastern
mediterranean
black
sea
region
volgograd
oblast
russia
dramat
develop
introduct
west
nile
viru
north
america
occurr
larg
outbreak
rapid
spread
across
us
subsequ
introduct
caribbean
south
america
hors
number
wild
bird
speci
notabl
crow
jay
affect
addit
human
total
case
west
nile
fever
case
neuroinvas
west
nile
diseas
report
us
highest
incid
middl
countri
texa
north
dakota
incid
neuroinvas
diseas
us
vari
per
interv
hors
affect
sinc
anim
diseas
sever
casefat
survivor
neurolog
sequela
human
case
fatal
enceph
survivor
sequela
moreov
incid
west
nile
hors
per
substanti
higher
human
anim
health
industri
rapidli
respond
veterinari
emerg
multipl
west
nile
vaccin
rapidli
develop
includ
live
vaccin
discuss
whole
virion
inactiv
dna
poxviru
vector
vaccin
first
vaccin
hors
market
year
introduct
viru
us
multipl
human
vaccin
develop
program
also
initi
mani
effort
discontinu
deceler
due
high
market
risk
associ
low
incid
slacken
public
concern
diseas
uncertain
regulatori
pathway
vaccin
approv
although
efficaci
vaccin
equid
establish
field
trial
prove
vaccin
efficaci
human
would
larg
expens
difficult
due
unpredict
occurr
west
nile
outbreak
applic
anim
rule
licens
west
nile
vaccin
plausibl
adjud
fda
sponsor
although
approach
develop
veterinari
human
vaccin
west
nile
technolog
similar
one
case
concurr
develop
program
undertaken
singl
compani
fact
illustr
current
statu
stovepip
separ
anim
human
health
biopharmaceut
industri
except
case
interest
model
vaccin
develop
zoonot
diseas
could
improv
within
month
identif
west
nile
etiolog
agent
initi
outbreak
affect
human
hors
new
york
acambi
public
trade
humanvaccin
biotechnolog
compani
appli
platform
technolog
yellow
fever
vaccin
develop
west
nile
vaccin
intent
develop
vaccin
hors
human
technolog
involv
replac
gene
encod
yellow
fever
vaccin
viru
envelop
e
protein
correspond
gene
west
nile
viru
chimer
vector
vaccin
platform
previous
use
compani
construct
chimer
vaccin
closelyrel
japanes
enceph
viru
time
vaccin
proven
highli
effect
protect
nonhuman
primat
intracerebr
challeng
virul
japanes
enceph
viru
two
new
vector
engin
one
wildtyp
west
nile
strain
e
protein
gene
one
e
gene
contain
three
attenu
mutat
former
neurovirul
mice
latter
attenu
thu
deem
suitabl
human
vaccin
princip
question
whether
yellow
fever
vector
would
infect
immun
hors
sinc
yellow
fever
hostrestrict
primat
viru
find
studi
sponsor
acambi
earli
colorado
state
univers
school
veterinari
medicin
hors
vaccin
west
nileyellow
fever
chimer
viru
yellow
fever
vaccin
viremia
antibodi
respons
determin
addit
vaccin
control
hors
challeng
intrathec
inject
high
dose
virul
west
nile
viru
follow
model
refer
protect
studi
chimer
japanes
enceph
vaccin
wherein
monkey
challeng
intracerebr
rout
studi
show
hors
inocul
chimer
vaccin
develop
neutral
antibodi
west
nile
protect
sever
intrathec
challeng
similar
develop
plan
success
follow
mutat
human
vaccin
version
use
nonhuman
primat
test
host
veterinari
human
vaccin
candid
develop
side
side
data
obtain
program
design
support
transit
advanc
clinic
trial
hors
human
acambi
licens
veterinari
vaccin
technolog
major
anim
health
compani
intervet
year
clinic
trial
materi
made
human
trial
intervet
complet
develop
veterinari
vaccin
prevenil
approv
usda
acambi
brought
human
vaccin
clinic
trial
timefram
subsequ
outlicens
technolog
sanofi
pasteur
expect
develop
veterinari
vaccin
progress
regulatori
pathway
substanti
outpac
human
vaccin
importantli
veterinari
applic
significantli
inform
human
vaccin
tabl
strength
limit
vaccin
anim
mean
control
zoonot
diseas
framework
see
tabl
develop
program
provid
use
inform
safeti
durabl
immun
immun
correl
protect
codevelop
veterinari
human
west
nile
vaccin
potenti
model
vaccin
exampl
vaccin
codevelop
anim
human
includ
vaccin
venezuelan
equin
enceph
rift
valley
fever
describ
certain
issu
aris
howev
may
need
consid
context
integr
effort
first
safeti
problem
aris
use
veterinari
vaccin
could
provok
regulatori
concern
liabil
problem
human
analog
although
safeti
issu
aris
briefli
due
anaphylaxi
type
reaction
hors
result
temporari
withdraw
prevenil
market
repercuss
human
analog
vaccin
rais
interest
question
whether
human
veterinari
regulatori
agenc
integr
inform
might
valu
either
develop
similar
vaccin
differ
speci
market
approv
obviou
overlook
area
applic
one
health
principl
second
immun
respons
veterinari
vaccin
gener
differenti
natur
infect
vaccin
anim
diva
basi
laboratori
test
allow
complianc
trade
restrict
cours
concern
regulatori
approv
human
vaccin
although
use
seroepidemiolog
vaccin
coverag
studi
exampl
problem
associ
diva
offlabel
use
commerci
hors
vaccin
protect
emu
eastern
equin
enceph
eee
sinc
combin
vaccin
eee
contain
equin
influenza
antigen
vaccin
elicit
crossreact
antibodi
avian
influenza
result
quarantin
chimer
west
nile
vaccin
describ
potenti
allow
diva
test
use
respons
yellow
fever
nonstructur
protein
express
vector
number
import
diseas
transmit
domest
anim
thenc
human
vaccin
domest
anim
potenti
protect
human
zoonos
either
indirectli
interrupt
transmiss
domest
anim
amplifi
host
transmiss
cycl
directli
prevent
spread
infect
anim
human
list
framework
ii
diseas
vaccin
shown
tabl
select
exampl
use
illustr
role
vaccin
domest
anim
prevent
human
diseas
brucella
spp
facult
intracellular
gramneg
bacteria
pathogen
domest
anim
human
brucellosi
caus
mainli
brucella
melitensi
infect
sheep
goat
brucella
abortu
cattl
brucella
sui
swine
occur
worldwid
highest
preval
middl
east
asia
africa
tropic
america
mediterranean
region
annual
incid
human
infect
estim
case
diseas
wide
acknowledg
underreport
brucella
cani
infect
dog
occur
worldwid
highest
preval
tropic
america
b
cani
diseas
human
report
especi
person
handl
breed
dog
immunosuppress
individu
human
brucellosi
acquir
contact
aerosol
spread
infect
anim
fomit
ingest
unpasteur
milk
undercook
meat
surprisingli
brucella
surviv
long
period
dust
anim
excreta
soil
meat
dairi
product
wild
anim
also
affect
sourc
infect
livestock
human
anim
brucellosi
caus
epididym
male
abort
placent
infertil
reduc
milk
product
femal
anim
human
diseas
protean
manifest
chronic
fatigu
relaps
fever
endocard
spondyl
osteomyel
arthriti
mening
prevent
human
diseas
control
brucellosi
livestock
long
public
health
prioriti
control
brucellosi
reli
princip
surveil
test
remov
infect
anim
importexport
anim
anim
product
control
provis
protect
exposur
wild
reservoir
elk
deer
bison
vaccin
antibiot
treatment
anim
regul
discourag
due
larg
dose
long
treatment
requir
concern
resist
old
empir
develop
live
attenu
vaccin
b
melitensi
vaccin
goat
sheep
b
abortu
vaccin
cattl
oral
b
sui
vaccin
use
wide
china
multipl
speci
elicit
cellular
immun
intracellular
pathogen
effect
type
vaccin
vaccin
spontan
rifampinresist
rough
mutant
approv
us
howev
live
vaccin
number
drawback
latter
includ
lack
abil
differenti
vaccin
immun
natur
immun
diva
interfer
surveil
export
control
procedur
pathogen
especi
abort
anim
vaccin
pregnanc
antibiot
resist
vaccin
strain
modest
efficaci
live
vaccin
use
livestock
also
caus
ill
human
vaccin
standalon
strategi
rare
care
evalu
larg
part
due
concern
qualiti
exist
vaccin
howev
vaccin
larg
credit
elimin
brucellosi
us
us
declar
free
brucellosi
cattl
control
brucellosi
china
recent
studi
greec
show
mass
vaccin
program
b
melitensi
vaccin
result
decreas
human
infect
number
new
vaccin
approach
includ
diva
vaccin
design
induc
orient
cellular
immun
investig
includ
safer
ration
design
mutat
live
vaccin
recombin
invas
escherischia
coli
recombin
subunit
microencapsul
vaccin
dna
vaccin
experiment
b
cani
vaccin
investig
mice
brucellosisfre
statu
achiev
us
wild
anim
reservoir
especi
bison
elk
threaten
reintroduc
diseas
vaccin
exist
vaccin
feasibl
deliveri
challeng
vero
cytotoxin
secret
gramneg
bacteria
import
caus
sporad
epidem
foodborn
ill
human
includ
gastroenter
hemorrhag
coliti
potenti
lethal
complic
hemolyticurem
syndrom
cattl
sheep
princip
reservoir
infect
transmiss
human
occur
via
food
meat
seed
veget
contamin
anim
fece
undercook
ground
beef
sourc
infect
approxim
onethird
human
case
recal
signific
econom
threat
meat
pack
distribut
industri
anim
concentr
feed
lot
slaughter
shed
bacteria
produc
lot
meat
high
rate
consider
variabl
occurr
contamin
develop
countri
variou
sanitari
measur
test
institut
reduc
risk
consum
remain
imperfect
vaccin
feed
lot
cattl
propos
measur
reduc
preval
durat
shed
risk
consum
bacteri
extract
vaccin
contain
protect
outer
membran
protein
condit
approv
usda
manufactur
epitopix
willmar
mn
fulli
approv
canadian
food
inspect
agenc
bionich
life
scienc
bellevil
ont
feedlot
cattl
receiv
dose
bionich
vaccin
week
apart
reduct
colorect
colon
fecal
shed
signific
reduct
magnitud
durat
shed
hurd
malladi
model
impact
vaccin
cattl
human
health
outcom
assum
efficaci
vaccin
adopt
rate
model
indic
reduct
incid
e
coli
human
ill
model
also
predict
signific
reduct
number
lot
contamin
ground
beef
detect
usda
would
substanti
econom
benefit
packer
distributor
vaccin
effect
condit
field
use
highli
depend
adopt
rate
vaccin
coverag
part
whether
cattl
complet
vaccin
seri
proscrib
schedul
interest
question
pay
vaccin
feedlot
cattl
econom
benefit
meat
industri
vaccin
reduc
cost
prevent
measur
test
vaccin
cost
simpli
top
cost
govern
agenc
concern
human
health
subsid
cost
without
empir
demonstr
human
health
benefit
sinc
ground
beef
contribut
onethird
human
infect
could
vaccin
use
mean
reduc
sourc
food
contamin
anoth
issu
use
current
vaccin
role
enterohemorrhag
e
coli
eg
human
diseas
diseas
caus
primarili
gramneg
bacterium
bartonella
hensela
transmit
domest
cat
agenc
cat
flea
ctenocephalid
feli
human
infect
occur
contact
spread
cat
includ
scratch
claw
contamin
blood
flea
fece
possibl
flea
bite
preval
infect
household
cat
us
approxim
stray
anim
high
preval
rate
found
develop
countri
diseas
human
manifest
fever
papul
follow
pustul
site
infect
lymphadenopathi
rare
complic
includ
mening
enceph
endocard
glomerulonephr
osteomyel
neuropsychiatr
abnorm
relaps
fever
splenomegali
human
infect
immunecompromis
individu
particularli
sever
approxim
case
hospit
caus
cat
scratch
diseas
estim
occur
annual
us
late
heska
corpor
anim
heath
compani
colorado
initi
program
develop
vaccin
household
cat
goal
limit
potenti
transmiss
bacteria
cat
human
unfortun
program
complet
vaccin
avail
present
given
fact
cat
rare
becom
ill
b
hensela
would
unusu
product
provid
protect
pet
owner
margin
real
benefit
target
speci
moreov
would
like
extrem
challeng
demonstr
health
benefit
human
rabi
fatal
infect
central
nervou
system
caus
rabi
viru
member
lyssaviru
genu
famili
rhabdovirida
estim
case
human
rabi
occur
annual
dog
bite
caus
success
vaccin
dog
human
rabi
first
demonstr
loui
pasteur
use
crude
nerv
tissu
prepar
howev
first
decad
centuri
develop
countri
continu
mani
develop
countri
today
ancient
practic
dog
popul
reduct
campaign
main
approach
rabi
control
method
repeatedli
proven
ineffect
dog
licens
vaccin
requir
introduc
unit
kingdom
gradual
local
state
level
us
begin
nation
requir
attain
mani
success
dog
vaccin
campaign
report
latin
american
countri
asia
countri
declar
erad
canin
rabi
notabl
unit
kingdom
japan
us
well
malaysia
singapor
taiwan
hong
kong
first
world
rabi
day
event
ultim
vision
promulg
canin
rabi
elimin
systemat
vaccin
howev
rabi
remain
signific
public
health
problem
due
absent
incomplet
dog
vaccin
mani
area
world
million
postexposur
treatment
rabi
vaccin
given
annual
cost
billion
worldwid
china
due
low
preval
canin
vaccin
sale
rabi
vaccin
human
postexposur
prophylaxi
outstrip
human
vaccin
account
annual
vaccin
sale
ie
million
dose
cost
million
requir
human
postexposur
vaccin
scale
repres
obviou
failur
public
health
sinc
play
role
contain
spread
rabi
canin
vector
high
rate
vaccin
coverag
dog
popul
exceed
requir
interrupt
rabi
transmiss
cycl
develop
oral
rabi
vaccin
allow
vaccin
freeroam
dog
could
restrain
vaccin
inject
well
vaccin
wild
anim
speci
sourc
infect
dog
oral
bait
vaccin
dog
success
deploy
trial
mani
countri
includ
turkey
thailand
sri
lanka
south
africa
philippin
world
health
organ
support
approach
supplement
program
substanti
popul
freerang
feral
dog
signific
increas
canin
vaccin
coverag
achiev
oral
rabi
vaccin
ad
program
standard
parenter
vaccin
oral
vaccin
dog
accomplish
use
commerci
bait
contain
live
modifi
rabi
vaccin
streetalabamadufferin
sad
strain
variant
attenu
copenhagen
strain
vaccinia
express
rabi
glycoprotein
gene
g
protein
detail
review
oral
rabi
vaccin
provid
framework
iii
hendra
viru
diseas
sever
fatal
infect
hors
human
australia
note
exampl
illustr
one
health
principl
diseas
prevent
control
especi
relev
new
vaccin
hors
introduc
hendra
member
henipaviru
genu
famili
paramyxovirida
reservoir
host
fruit
bat
pteropu
spp
viru
spread
bat
hors
contact
includ
respiratori
droplet
food
fomit
contamin
bat
urin
contact
sick
hors
report
human
infect
result
contact
infect
hors
hendra
viru
diseas
first
describ
human
equin
case
occur
coastal
queensland
new
south
wale
posit
bat
detect
northern
territori
total
death
equid
report
outbreak
high
casefat
rate
case
fatal
occur
human
includ
hors
trainer
veterinarian
contact
sick
hors
diseas
manifest
sever
system
ill
respiratori
symptom
acut
relaps
enceph
swine
appear
suscept
experiment
infect
nipah
viru
close
relat
batborn
agent
se
asia
caus
outbreak
sever
fatal
diseas
swine
human
novemb
pfizer
anim
health
launch
equivac
hev
adjuv
subunit
protein
vaccin
prevent
hendra
viru
diseas
hors
australia
sinc
hors
major
sourc
contact
spread
hendra
viru
human
vaccin
promis
make
import
contribut
human
health
well
fear
acquir
diseas
also
constrain
equin
veterinari
practic
australia
vaccin
mitig
problem
develop
equivac
hev
collabor
effort
pfizer
csiro
australian
anim
health
laboratori
howev
support
develop
program
also
provid
human
medic
research
us
uniform
servic
univers
health
scienc
support
henri
jackson
foundat
advanc
militari
medicin
provision
approv
limit
use
vaccin
obtain
earli
full
approv
novemb
vaccin
solubl
recombin
glycoprotein
g
hendra
viru
ligand
cell
attach
antibodi
protein
neutral
cell
receptor
bind
viru
vaccin
protect
hors
ferret
experiment
infect
appear
crossprotect
nipah
viru
avail
equivac
hev
lead
rapid
uptak
hors
owner
australia
equin
hors
race
industri
australia
larg
contribut
billion
dollar
total
gross
domest
product
hendra
viru
hors
notifi
diseas
australian
jurisdict
properti
hors
case
locat
quarantin
anim
infect
euthan
occurr
least
one
hendra
viru
outbreak
annual
sinc
high
lethal
diseas
rais
consider
awar
australia
sinc
human
case
zoonosi
result
contact
infect
hors
vaccin
hors
hendra
viru
promis
highli
effect
strategi
prevent
human
case
rift
valley
fever
envelop
singlestrand
segment
rna
viru
belong
phleboviru
genu
famili
bunyavirida
occur
africa
intermitt
extens
arabian
peninsula
rift
valley
fever
viru
caus
explos
econom
damag
outbreak
diseas
cattl
sheep
stillbirth
abort
high
mortal
young
anim
adult
anim
caus
mortal
sheep
cattl
goat
human
typic
develop
selflimit
nonspecif
febril
ill
complic
cours
hemorrhag
fever
syndrom
enceph
hepat
renal
failur
retin
casefat
rate
sever
ill
hospit
patient
high
viru
transmit
livestock
livestock
human
agenc
mosquito
vector
addit
human
commonli
acquir
infect
contact
aerosol
rout
handl
treat
butcher
infect
livestock
viru
persist
meat
week
ecolog
rift
valley
fever
reason
behind
period
emerg
subject
intens
studi
brief
reservoir
infect
aed
mosquito
especi
ae
linneatopenni
maintain
viru
transovari
transmiss
dessicationresist
ova
contain
viru
remain
depress
earth
dambo
flood
raini
season
subsequ
emerg
infect
adult
aed
mosquito
infect
virem
livestock
turn
serv
sourc
amplifi
viru
transmiss
varieti
mosquito
vector
approv
vaccin
prevent
rift
valley
fever
human
although
number
candid
develop
academ
govern
laboratori
vaccin
cattl
sheep
repres
strategi
prevent
diseas
speci
therebi
interrupt
viru
transmiss
human
rift
valley
fever
epizoot
extent
predict
base
rainfal
pattern
surveil
diseas
livestock
surveil
provid
opportun
rapid
intervent
particularli
singledos
vaccin
like
live
attenu
vaccin
would
protect
viremia
cattl
sheep
prevent
mosquito
infect
addit
routin
vaccin
livestock
interepizoot
period
product
capabl
induc
durabl
protect
immun
long
rang
goal
support
conceptu
model
howev
mani
obstacl
livestock
immun
africa
includ
access
polici
regulatori
approv
cold
chain
commerci
viabil
addit
diva
requir
driven
regul
prohibit
export
livestock
meat
countri
experienc
rift
valley
fever
obstacl
vaccin
implement
could
overcom
develop
improv
vaccin
two
old
veterinari
vaccin
live
smithburn
vaccin
develop
use
techniqu
serial
passag
mous
brain
similar
appli
earli
develop
french
neurotrop
vaccin
yellow
fever
formalin
inactiv
vaccin
commerci
avail
onderstepoort
institut
south
africa
howev
smithburn
vaccin
produc
cell
report
caus
teratogen
abort
use
pregnant
anim
use
countri
endem
rift
valley
fever
due
concern
revers
inactiv
vaccin
also
grown
cell
cultur
requir
multipl
dose
effect
probabl
rel
short
durabl
make
less
desir
intervent
propos
nonetheless
inactiv
vaccin
success
use
interrupt
rift
valley
fever
outbreak
south
african
sheep
inde
follow
larg
epidem
rift
valley
fever
egypt
veterinari
serum
vaccin
research
institut
cairo
egypt
produc
formalininactiv
vaccin
cell
use
epidem
strain
match
local
circul
strain
compar
south
african
strain
anoth
inactiv
vaccin
tsigsd
develop
us
armi
human
immun
grown
diploid
fetal
rhesu
lung
cell
test
clinic
shown
well
toler
immunogen
nineti
subject
develop
neutral
titer
shown
higher
protect
level
passiv
immunizationchalleng
studi
hamster
addit
requir
multipl
dose
primari
booster
immun
inactiv
rift
valley
fever
vaccin
disadvantag
requir
high
biocontain
facil
manufactur
recent
year
substanti
progress
develop
newer
vaccin
vaccin
develop
project
collabor
human
veterinari
research
group
addit
moder
level
support
us
govern
rift
valley
fever
credibl
threat
natur
intent
bioterrorist
introduct
nevertheless
despit
promis
technic
result
insuffici
support
industri
govern
propel
new
vaccin
candid
use
obviou
advantag
rapid
onset
durabl
immun
associ
live
vaccin
develop
improv
live
vaccin
focu
research
us
armi
investig
attempt
induc
attenu
mutat
two
rift
valley
fever
viru
strain
isol
egyptian
epidem
live
vaccin
develop
virul
strain
passag
cell
presenc
mutagen
result
temperatur
sensit
viru
amino
acid
mutat
attenu
demonstr
multipl
anim
model
reassort
studi
show
attenu
mutat
redund
resid
three
gene
segment
develop
undertaken
us
armi
medic
research
institut
infecti
diseas
intent
produc
vaccin
human
anim
immun
vaccin
clinic
test
human
volunt
shown
welltoler
highli
immunogen
armi
investig
collabor
usda
conduct
number
studi
vaccin
sheep
cow
includ
neonat
pregnant
lactat
anim
studi
show
caus
low
viremia
attend
clinic
sign
viru
secret
milk
abort
teratogen
vaccin
given
midto
late
term
pregnanc
highli
immunogen
protect
livestock
virul
challeng
howev
ewe
vaccin
earli
pregnanc
show
low
incid
abort
teratogen
indic
residu
virul
vaccin
improv
genet
stabil
safeti
revers
genet
techniqu
use
introduc
delet
rna
segment
gene
encod
respect
nss
nsm
protein
two
delet
mutant
evalu
safeti
immunogen
pregnant
ewe
calv
morril
jc
person
commun
posit
result
nsm
delet
make
attract
candid
veterinari
human
vaccin
clear
safeti
signal
ewe
inocul
earlymid
pregnanc
safeti
studi
requir
rule
low
incid
abortionteratogen
seen
parent
earlyterm
ewe
unfortun
human
trial
yet
perform
ration
design
deriv
third
live
vaccin
design
clone
plaquederiv
clone
central
african
strain
rift
valley
fever
isol
human
subject
found
natur
attenu
mice
infram
delet
nss
gene
observ
basi
modifi
vaccin
ns
gene
delet
describ
collabor
human
veterinari
research
led
studi
ewe
show
clone
highli
immunogen
caus
abort
anoth
attenu
vaccin
design
develop
reassort
clone
contain
segment
clone
l
segment
strain
attenu
domain
parent
vaccin
candid
number
live
replic
nonrepl
heterolog
viral
vector
express
rift
valley
fever
glycoprotein
nonstructur
protein
investig
mice
elicit
immun
respons
protect
challeng
vector
includ
lumpi
skin
diseas
capripoxviru
alphaviru
vee
sindbi
replicon
newcastl
diseas
viru
adenoviru
modifi
vaccinia
ankara
sever
construct
use
immun
sheep
andor
cattl
lumpi
skin
diseas
viru
newcastl
diseas
viru
sindbi
replicon
somewhat
variabl
success
comprehens
review
see
indran
ikegami
boshra
et
al
live
vector
promis
approach
new
rift
valley
fever
vaccin
particularli
veterinari
vaccin
may
problem
homolog
boost
light
antivector
immun
variou
primeboost
strategi
propos
plasmid
dna
vaccin
see
would
except
difficult
implement
immun
livestock
field
thu
impract
subunit
protein
produc
insect
cell
viruslik
particl
dna
vaccin
rift
valley
fever
also
earli
stage
develop
approach
potenti
advantag
safeti
thermost
storag
distribut
may
requir
multipl
dose
provid
less
durabl
immun
live
vaccin
thu
less
desir
product
framework
ii
implement
overal
remain
seen
mani
rift
valley
fever
vaccin
develop
progress
regulatori
approv
whether
integr
veterinari
human
health
polici
base
immun
livestock
africa
togeth
predict
surveil
abort
impend
outbreak
lead
long
rang
control
import
diseas
vee
mosquitoborn
singl
strand
positivesens
envelop
rna
viru
belong
alphaviru
genu
famili
togavirida
medic
import
member
alphaviru
genu
includ
eastern
western
equin
enceph
virus
vee
viru
subtyp
identifi
antigen
genom
analys
number
addit
varieti
subtyp
iab
ic
caus
epizoot
diseas
equid
associ
zoonot
infect
human
epizoot
hors
donkey
infect
strain
develop
high
viremia
serv
primari
host
infect
mosquito
vector
therefor
indirect
sourc
human
infect
acquir
mosquito
bite
contrast
enzoot
subtyp
iivi
maintain
natur
cycl
involv
rodent
speci
mosquito
amplifi
equid
virem
host
caus
sporad
ill
human
equid
deadend
host
epizoot
ic
viru
result
mutat
select
virul
equinecompet
virus
enzoot
strain
particularli
id
variant
vee
iab
virus
caus
larg
epizoot
south
america
associ
human
epidem
enceph
seri
major
subtyp
iab
ic
epizoot
occur
northern
south
america
viru
spread
north
central
america
mexico
texa
cumul
econom
medic
impact
vee
outbreak
devast
equid
human
case
vee
iab
epizoot
believ
spawn
inject
hors
inactiv
veterinari
vee
vaccin
contain
residu
live
viru
like
occur
trinidad
nicaragua
probabl
widespread
problem
past
vee
ic
reemerg
venezuela
colombia
estim
equid
death
human
case
enceph
sinc
vee
caus
acut
incapacit
ill
human
viru
effici
infect
via
aerosol
rout
develop
us
soviet
union
offens
biolog
weapon
part
program
vaccin
protect
militari
personnel
also
develop
us
live
attenu
viru
develop
us
armi
medic
research
develop
command
usamrdc
empir
passag
prototyp
trinidad
donkey
subtyp
iab
viru
fetal
guinea
pig
heart
cell
cultur
develop
live
vaccin
follow
poor
experi
chemic
inactiv
vaccin
anim
model
live
vaccin
protect
aerosol
challeng
howev
vaccin
number
drawback
human
vaccin
includ
failur
immun
vaccine
moderatetosever
reactogen
subject
human
remain
investig
product
use
sole
protect
laboratori
worker
approxim
person
vaccin
sinc
viru
acquir
mutat
empir
passag
seri
guinea
pig
heart
cell
attenu
appear
link
noncod
region
envelop
glycoprotein
substitut
appear
subject
revers
vaccin
host
addit
isol
mosquito
vector
field
use
illustr
potenti
secondari
spread
mutat
recombin
event
investig
formalininactiv
vaccin
design
also
develop
usamrdc
use
follow
prime
seroconvert
nonrespond
sinc
hors
relat
speci
sever
affect
epizoot
sourc
mosquito
vector
infect
human
obviou
need
singl
dose
veterinari
vaccin
evok
rapid
immun
us
armi
investig
explor
use
live
attenu
human
vaccin
immun
equid
begin
limit
field
use
vaccin
colombia
howev
epizoot
vee
appear
first
time
central
america
guatemala
may
spread
southward
costa
rica
northward
us
consider
urgenc
util
vaccin
strategi
control
diseas
hors
donkey
mule
us
militari
respond
rapidli
request
vaccin
guatemala
el
salvador
vaccin
produc
stockpil
merrel
nation
laboratori
swiftwat
pa
contract
usamrdc
purpos
biolog
defens
million
dose
given
equida
us
mexico
central
america
collabor
studi
also
undertaken
agenc
concern
human
anim
health
usamrdc
nih
usda
fulli
explor
biolog
vaccin
hors
ultim
lead
licensur
commerci
anim
health
industri
live
vaccin
inactiv
vaccin
combo
eastern
western
equin
enceph
vaccin
vaccin
credit
rapid
curtail
outbreak
histori
vee
exemplifi
mani
one
health
principl
includ
prevent
human
case
domest
anim
vaccin
use
singl
vaccin
product
anim
human
agenc
us
armi
concern
human
health
engag
veterinari
human
vaccin
develop
provid
solut
curtail
emerg
zoonosi
larg
epizoot
vaccin
deploy
epidem
colombia
creat
immun
barrier
spread
viru
recent
effort
focus
develop
improv
vee
vaccin
human
less
reactogen
immunogen
manufactur
accept
substrat
lower
risk
revers
virul
mosquito
transmiss
addit
vaccin
crossprotect
enzoot
vee
subtyp
need
vee
id
endem
colombia
peru
venezuela
ecuador
ie
subtyp
circul
southern
mexico
aguilar
et
al
postul
diseas
caus
vee
confus
clinic
dengu
endem
area
dengu
case
may
actual
due
vee
enzoot
subtyp
virus
subtyp
id
pose
everpres
risk
mutat
chang
produc
high
viremia
epizoot
transmiss
equid
happen
vaccin
ration
design
vaccin
epizoot
subtyp
iab
genom
insert
cleavagesign
mutat
combin
gene
resuscit
mutat
good
safeti
profil
immunogen
protect
laboratori
anim
includ
nonhuman
primat
retain
degre
neurovirul
suckl
mice
virul
inocul
intracrani
juvenil
monkey
also
evalu
hors
vaccin
safe
highli
immunogen
subcutan
dose
low
plaqueform
unit
shown
protect
hors
challeng
virul
subtyp
iab
viru
unfortun
prove
reactogen
human
phase
trial
thu
develop
human
veterinari
use
stop
viru
subsequ
formalin
inactiv
investig
adjuv
replac
vaccin
live
live
vector
approach
improv
vee
vaccin
investig
laboratori
anim
includ
chimer
viru
construct
nonstructur
gene
sindbi
structur
gene
vee
vee
replicon
vaccin
vaccinia
recombin
none
approach
reach
advanc
develop
matter
time
anoth
vee
outbreak
emerg
tropic
america
substanti
risk
crossbord
spread
prospect
vaccin
intervent
diminish
dwindl
support
new
vaccin
increas
concern
vaccin
safeti
zoonot
diseas
maintain
transmiss
cycl
involv
wild
mammal
bird
howev
difficulti
vaccin
specif
host
speci
wildlif
immun
mean
prevent
spread
domest
anim
human
appli
diseas
barrier
implement
wild
anim
vaccin
includ
involv
multipl
speci
natur
transmiss
cycl
ii
safeti
concern
nontarget
speci
iii
high
reproduct
rate
popul
turnov
iv
fastidi
feed
behavior
difficulti
design
effect
bait
v
difficult
deliveri
due
high
convers
low
popul
densiti
target
speci
vi
environment
concern
releas
genet
modifi
organ
vii
difficulti
design
effect
formul
oral
immun
viii
instabl
vaccin
vector
prevail
environment
condit
ix
requir
low
unit
cost
govern
fund
vaccin
purchas
deliveri
nevertheless
target
immun
wild
anim
reservoir
subject
consider
interest
futur
research
control
infecti
agent
affect
domest
anim
human
also
control
wildlif
diseas
one
exampl
latter
effort
develop
mean
immun
great
ape
affect
ebola
viru
central
africa
vaccin
previous
develop
human
use
asid
rabi
vaccin
deliv
oral
bait
wellestablish
wildlif
vaccin
limit
success
two
promis
exampl
earlystag
vaccin
applic
describ
lyme
diseas
mycobacterium
bovi
addit
experiment
immun
protect
prairi
dog
cynomi
ludovicianu
use
raccoon
poxviru
recombin
oral
bait
vaccin
ballist
vaccin
bison
b
abortu
describ
plagu
global
local
zoonot
diseas
rodent
wildlif
reservoir
would
appear
target
particular
interest
futur
research
mani
possibl
target
new
framework
iii
vaccin
futur
research
field
encourag
unit
state
lyme
diseas
common
vectorborn
diseas
common
infecti
diseas
overal
also
major
increas
public
health
problem
europ
approxim
case
report
us
annual
number
doubl
last
year
howev
meet
august
center
diseas
control
prevent
cdc
report
annual
incid
infect
believ
higher
ie
case
although
lyme
diseas
occur
across
countri
incid
highest
northeast
north
central
state
us
lyme
diseas
caus
spirochet
borrelia
burgdorferi
amplifi
spring
summer
cycl
princip
involv
ixod
scapulari
tick
field
mice
mice
persist
infect
repres
reservoir
infect
natur
b
burgdorferi
pass
transtadi
nymphal
adult
tick
infect
human
dog
speci
develop
clinic
diseas
deadend
host
human
diseas
manifest
protean
syndrom
start
local
skin
infect
erythema
migran
progress
multisystem
diseas
variabl
lassitud
arthriti
carditi
mening
neurolog
manifest
increas
incid
geograph
expans
lyme
diseas
high
incid
tick
exposur
difficulti
recogn
remov
attach
tick
due
small
size
difficult
differenti
diagnosi
troublesom
potenti
sever
clinic
manifest
medic
controversi
treatment
chronic
diseas
lyme
diseas
emerg
high
prioriti
public
health
intervent
vaccin
human
would
appear
logic
costeffect
mean
prevent
diseas
veterinari
vaccin
dog
wide
use
proven
modestli
effect
howev
wherea
safe
highli
effect
vaccin
human
develop
none
avail
distribut
today
glaxo
smithklin
lymerix
vaccin
approv
withdrawn
compani
princip
commerci
reason
decis
lament
given
increas
incid
diseas
new
lyme
diseas
vaccin
human
activ
b
burgdorferi
speci
caus
lyme
diseas
europ
develop
baxter
bioscienc
phase
ii
develop
uncertain
whether
reach
market
nevertheless
vaccin
establish
critic
immunolog
principl
human
vaccin
compos
recombin
ospa
protein
dog
vaccin
ospa
ospc
work
via
antibodymedi
mechan
ospa
express
borrelia
spirochet
midgut
infect
tick
sinc
tick
vector
begin
transmit
borrelia
h
initi
blood
feed
ospa
specif
antibodi
imbib
blood
meal
vaccin
host
kill
bacteria
block
transmiss
similar
ospa
antibodi
respons
could
evok
natur
reservoir
host
b
burgdoferi
peromyscu
spp
field
mice
may
possibl
interrupt
transmiss
cycl
reduc
preval
infect
nymphal
adult
tick
respons
human
canin
infect
proof
concept
obtain
field
studi
peromyscu
leucopu
mice
trap
vaccin
subcutan
inject
ospa
reduct
preval
b
burgdorferi
nymphal
tick
seen
follow
year
howev
practic
vaccin
deliveri
effect
immun
mice
wild
requir
thermost
oral
bait
vaccin
match
high
popul
densiti
rapid
popul
turnov
reservoir
host
effect
dilut
nontarget
speci
play
role
b
burgdorferi
transmiss
two
promis
live
oral
vaccin
approach
investig
laboratori
bacteri
e
coli
vector
viral
vector
vaccinia
express
ospa
e
coli
vector
contain
oral
bait
formul
ingest
multipl
time
elicit
antiospa
antibodi
protect
laboratori
wild
p
leucopu
mice
needl
tick
challeng
field
studi
oral
bait
vaccin
sponsor
cdc
perform
result
anticip
interest
compani
us
biolog
inc
engag
bring
vaccin
market
vaccinia
technolog
rest
shoulder
success
oral
bait
vaccin
wildlif
rabi
see
test
laboratori
laboratori
mice
immun
gavag
vaccinia
express
ospa
success
immun
singl
dose
protect
tick
challeng
peromyscu
consum
oral
bait
vaccin
also
significantli
protect
challeng
infect
tick
although
vaccinia
vector
look
promis
commerci
endeavor
yet
emerg
support
develop
e
coli
vaccinia
oral
vaccin
requir
special
formul
bait
incorpor
vaccin
bait
rather
liquid
sachet
embed
bait
use
deliveri
rabi
vaccin
mani
question
surround
applic
oral
bait
vaccin
target
reservoir
host
includ
efficaci
approach
field
high
densiti
bait
requir
cost
sustain
local
state
fund
program
aim
distribut
bait
role
speci
target
vaccin
lyme
diseas
mainten
cycl
partial
effect
risk
acquir
lyme
diseas
may
reduc
public
would
still
need
take
precaut
tick
bite
nevertheless
given
lack
vaccin
human
high
level
public
concern
lyme
diseas
high
risk
children
local
natur
b
burgdorferi
transmiss
allow
geospati
focus
control
effort
possibl
homeown
may
motiv
play
activ
role
distribut
bait
idea
appeal
bovi
caus
tuberculosi
wide
array
domest
wild
anim
remain
major
veterinari
health
problem
worldwid
caus
sever
econom
loss
livestock
diseas
death
export
restrict
human
becom
infect
ingest
raw
milk
undercook
meat
aerosol
rout
infect
anim
human
develop
countri
pasteur
testandslaught
program
control
diseas
zoonot
infect
rel
rare
account
tuberculosi
case
develop
countri
practic
measur
remain
common
although
data
preval
exist
wild
anim
major
sourc
infect
domest
livestock
control
measur
aim
control
bovi
cull
wildlif
reservoir
problemat
inconsist
result
ethic
concern
vaccin
wildlif
attract
altern
control
measur
especi
sinc
tradit
tuberculosi
vaccin
bacil
calmetteguerin
bcg
deriv
bovi
effect
oral
administ
exampl
wildlif
serv
mainten
host
bovi
sourc
infect
livestock
includ
whitetail
deer
us
wild
boar
red
fallow
deer
europ
badger
unit
kingdom
african
buffalo
synceru
caffer
south
africa
brushtail
possum
trichosuru
vulpecula
new
zealand
brushtail
possum
experiment
vaccin
use
oral
bcg
shown
resist
challeng
bovi
proof
concept
provid
field
studi
endem
area
new
zealand
possum
trap
manual
vaccin
use
oral
deliv
bcg
lipid
matrix
formul
vaccin
control
anim
recaptur
interv
vaccin
anim
receiv
vaccin
studi
end
studi
ha
studi
area
depopul
anim
assess
clinic
subclin
bovi
infect
vaccin
efficaci
natur
acquir
tuberculosi
author
conclud
oral
vaccin
possum
could
practic
strategi
contribut
elimin
bovi
livestock
although
field
studi
demonstr
control
via
freeli
consum
bait
vaccin
captiv
possum
shown
consum
vaccin
flavor
bait
rabi
transmit
specif
wild
carnivor
reservoir
host
serv
sourc
spillov
infect
wild
carnivor
infect
domest
anim
human
oral
rabi
vaccin
initi
deploy
europ
control
rabi
red
fox
vulp
vulp
use
modifi
live
viru
vaccin
concept
began
work
georg
baer
cdc
show
fox
could
oral
immun
modifi
live
viru
live
attenu
evelynrokitnickiabelseth
era
vaccin
streetalabamadufferin
sad
virus
employ
experiment
field
studi
numer
studi
confirm
captiv
wild
fox
could
oral
immun
varieti
bait
contain
vaccin
steck
colleagu
initi
wild
fox
rabi
control
program
swiss
alp
use
oral
bait
vaccin
consist
chicken
head
vaccin
tetracyclin
biomark
contain
made
polyvinyl
chlorid
aluminum
foil
insert
scalp
trial
demonstr
fox
ingest
bait
next
year
success
fox
rabi
control
program
carri
mani
european
countri
late
use
bait
distribut
fix
wing
aircraft
helicopt
rather
ground
result
elimin
terrestri
rabi
sever
countri
larg
scale
distribut
labori
chicken
head
method
bait
gave
way
commerci
manufactur
mold
extrud
bait
variou
kind
consist
fish
meal
bone
meal
fat
pouch
blister
contain
liquid
vaccin
viru
vaccin
current
use
europ
eg
rabigen
virbac
laboratori
franc
modifi
live
attenu
rabi
viru
deriv
origin
sad
vaccin
addit
mutat
codon
amino
acid
rabi
g
protein
increas
genet
stabil
viru
recombin
vaccinia
viru
copenhagen
strain
express
era
strain
rabi
g
protein
rabor
merial
corp
rabi
g
protein
gene
insert
thymidin
kinas
gene
vaccinia
result
attenu
compar
parent
viru
durat
oral
rabi
immun
least
month
adult
red
fox
suffici
provid
herd
immun
reduc
reproduct
rate
r
less
modifi
live
viru
vaccin
thermolabil
vaccinia
requir
c
storag
retain
pathogen
nontarget
speci
pose
safeti
risk
human
expos
inadvert
consequ
recombin
vaccinia
oral
rabi
vaccin
approv
wildlif
immun
us
vaccin
consist
fishmeal
fish
oil
bound
polym
ethylen
vinyl
acet
contain
vaccin
plastic
pouch
held
place
wax
mixtur
immun
vaccinia
modifi
live
viru
occur
buccal
mucosa
tonsil
vaccin
poorli
effect
ingest
one
studi
consumpt
red
fox
singl
bait
contain
vaccinia
result
protect
virul
rabi
half
anim
observ
suggest
high
bait
densiti
repeat
vaccin
import
effect
control
wild
bait
densiti
distribut
europ
gener
rang
baitskm
result
anim
potenti
immun
posit
tetracyclin
biomark
addit
distribut
densiti
feed
habit
may
also
import
sinc
anim
observ
pick
apart
bait
consum
bait
portion
control
terrestri
wildlif
rabi
success
part
europ
challeng
area
due
divers
carnivor
involv
transmiss
differ
rabi
viru
variant
arctic
region
specif
rabi
variant
maintain
arctic
fox
spillov
infect
red
fox
skunk
raccoon
dog
vaccin
practic
domest
sledg
dog
anim
may
sever
impact
contact
rabid
fox
human
dog
owner
place
consider
risk
experiment
oral
vaccin
arctic
fox
success
limit
experi
field
ontario
canada
control
arctic
rabi
variant
red
fox
use
oral
bait
vaccin
success
viru
still
occur
result
spillov
transmiss
skunk
effici
immun
recombin
vaccinia
vaccin
oral
bait
recombin
vaccinia
vaccin
primarili
use
control
raccoon
rabi
expand
begin
enzoot
area
florida
northward
westward
involv
mani
state
eastern
us
well
new
brunswick
quebec
canada
control
program
reli
distribut
vaccin
bait
specif
zone
rabi
activ
particularli
along
appalachian
ridg
enhanc
surveil
ring
vaccin
evid
spread
diseas
judg
absenc
spread
beyond
zone
vaccin
distribut
program
work
well
despit
rel
low
preval
rabi
antibodi
approxim
sampl
raccoon
possibl
preexist
immun
raccoonpox
viru
may
interfer
immun
vaccinia
econom
largescal
oral
vaccin
program
us
model
gener
favor
addit
control
raccoon
rabi
success
use
vaccin
made
control
gray
fox
urocyon
cinereoargenteu
variant
rabi
west
texa
contrast
raccoon
higher
preval
rabi
antibodi
attribut
vaccin
found
gray
fox
rabi
coyot
cani
latran
respons
epizoot
canin
rabi
part
us
control
oral
bait
vaccin
campaign
contribut
elimin
canin
rabi
skunk
remain
problemat
speci
vaccin
control
rabi
skunk
import
spillov
host
arctic
fox
raccoon
rabi
big
brown
bat
rabi
viru
variant
although
vaccinia
vector
vaccin
suffici
effect
skunk
promis
result
obtain
replicationcompet
adenoviru
type
vector
express
rabi
g
protein
aerial
distribut
vaccin
onrab
artemi
technolog
guelph
show
high
rate
immun
raccoon
arctic
fox
modest
seroconvers
differ
plot
skunk
probabl
due
lower
rate
bait
accept
onrab
approv
canadian
regulatori
author
control
rabi
skunk
raccoon
fox
investig
us
notabl
failur
anim
vaccin
mean
prevent
zoonot
diseas
human
illustr
limit
approach
shown
tabl
japanes
enceph
mosquitoborn
flaviviru
close
relat
west
nile
viru
endem
asia
nearli
billion
peopl
risk
infect
hors
human
deadend
host
framework
immun
wide
practic
mani
part
asia
long
record
success
pig
import
domest
anim
amplifi
host
infect
rice
paddybreed
culex
spp
vector
result
spillov
infect
human
moreov
infect
pregnant
sow
lead
abort
stillbirth
infect
boar
may
reduc
spermatogenesi
infertil
framework
ii
immun
swine
previous
major
initi
japan
use
live
attenu
vaccin
howev
exceedingli
difficult
vaccin
piglet
born
spring
earli
summer
narrow
window
loss
interf
matern
antibodi
contribut
viru
amplif
practic
vaccin
abandon
favor
reloc
piggeri
area
culex
breed
bite
activ
elsewher
asia
obstacl
preclud
consider
framework
ii
vaccin
japanes
enceph
includ
preval
small
piggeri
locat
near
vector
breed
site
feral
swine
import
wild
ardeid
bird
waterfowl
viru
transmiss
moreov
mani
area
asia
less
develop
japan
undergo
rapid
urban
locat
pig
hold
control
often
locat
near
rice
paddi
urban
center
consequ
focu
long
human
vaccin
primari
mean
prevent
case
studi
exemplifi
factor
limit
applic
framework
ii
vaccin
need
custom
vaccin
breed
husbandri
practic
time
domest
anim
target
role
wild
anim
feral
domest
anim
addit
amplifi
host
transmiss
cycl
difficult
access
given
larg
scale
geograph
complex
domest
anim
popul
q
fever
caus
intracellular
gramneg
bacterium
coxiellla
burnetii
import
worldwid
infect
rumin
serv
sourc
infect
human
especi
larg
number
anim
concentr
q
fever
major
occup
hazard
abattoir
farm
worker
veterinarian
person
involv
handl
distribut
anim
anim
product
dramat
outbreak
recent
occur
highintens
goat
farm
netherland
human
case
death
transmiss
c
burnetii
occur
direct
spread
domest
anim
anim
human
infect
anim
shed
bacteria
urin
fece
vagin
secret
product
concept
milk
tick
also
reservoir
bacteria
natur
sourc
infect
livestock
rumin
particularli
goat
sheep
develop
pneumonia
abort
stillbirth
prematur
deliveri
deliveri
weak
offspr
herd
affect
prolong
period
caus
signific
econom
loss
two
development
stage
c
burnetii
smallcel
variant
scv
extracellular
form
metabol
activ
intracellular
largecel
variant
scv
highli
resist
degrad
persist
environ
long
period
time
infect
human
acquir
princip
aerosol
rout
via
dust
contain
sporelik
scv
form
oral
rout
infect
ingest
unpasteur
milk
secondari
human
diseas
character
influenzalik
ill
may
complic
pneumonia
endocard
pregnant
women
abort
fetal
death
persontoperson
transmiss
occur
rare
approxim
infect
person
may
develop
chronic
infect
variou
manifest
prophylact
vaccin
play
role
control
q
fever
livestock
practic
reliabl
mean
prevent
human
infect
russia
live
attenu
vaccin
use
mani
year
anim
human
caus
persist
infect
consid
safe
use
elsewher
europ
coxevac
formalin
inactiv
strain
rsa
phase
bacteri
form
smooth
form
complet
surfac
lipopolysaccharid
use
goat
cattl
reduc
incid
shed
effect
pregnant
chronic
infect
anim
live
phase
vaccin
also
diva
present
substanti
issu
export
control
australia
inactiv
phase
vaccin
prepar
henzerel
strain
market
human
csl
ltd
qvax
howev
sever
reaction
occur
person
previous
natur
infect
c
burnetii
skin
test
ensur
absenc
exposur
requir
clearli
improv
vaccin
need
livestock
human
variou
attempt
recombin
vaccin
disappoint
problem
framework
ii
vaccin
q
fever
due
multipl
factor
includ
imperfect
vaccin
limit
efficaci
vaccin
parou
anim
difficulti
recogn
diseas
interven
expediti
rapid
widespread
contamin
environ
scv
form
last
problem
major
reason
livestock
vaccin
reliabl
mean
protect
human
exposur
year
studi
sheep
vaccin
phase
vaccin
show
proport
anim
shed
bacteria
fece
markedli
reduc
year
elimin
year
c
burnetii
still
present
environment
sampl
final
live
veterinari
vaccin
may
pose
risk
inadvert
infect
human
handl
vaccin
vaccin
anim
exampl
includ
live
brucella
orf
contagi
ecthyma
vaccin
topic
beyond
scope
review
import
sever
context
inde
littl
known
risk
human
pathogen
anim
immun
swine
poultri
worker
influenza
mean
prevent
introduct
human
influenza
virus
anim
emphas
mean
prevent
emerg
reassort
strain
immun
human
prevent
spread
virus
captiv
nonhuman
primat
often
practic
includ
vaccin
influenza
hepat
b
measl
prevent
anim
diseas
human
diseas
use
vaccin
wellestablish
principl
potenti
synergi
achiev
concurr
deliveri
human
anim
vaccin
develop
countri
set
diseas
affect
livestock
human
clear
commerci
incent
develop
vaccin
product
framework
vaccin
tabl
howev
develop
effort
gener
segreg
anim
human
health
divis
industri
academia
separ
regulatori
pathway
result
potenti
wast
resourc
duplic
scientif
endeavor
interestingli
one
compani
akso
nobel
anim
health
compani
decid
strateg
move
human
vaccin
develop
drew
veterinari
scientist
staff
program
point
review
isol
success
exampl
eg
west
nile
vaccin
codevelop
vaccin
veterinari
human
indic
obvious
effici
strategi
broaden
commerci
public
health
opportun
futur
effort
along
similar
line
consid
case
case
basi
depend
medic
need
gener
valu
closer
connect
human
veterinari
vaccin
regulatori
scienc
applic
domest
anim
model
develop
infecti
diseas
cancer
vaccin
sever
issu
relat
diva
requir
liabil
concern
mention
prevent
zoonot
diseas
human
mean
vaccin
domest
framework
ii
wild
framework
iii
anim
attract
underexploit
concept
obstacl
may
limit
commerci
incent
tabl
market
exist
govern
may
princip
custom
case
approv
oral
bait
rabi
vaccin
reservoirtarget
lyme
diseas
vaccin
develop
thu
public
health
gain
intervent
need
compel
must
offset
cost
develop
implement
goal
far
easier
justifi
vaccin
also
prevent
diseas
econom
valuabl
anim
speci
profit
incent
anim
vaccin
clear
social
gain
improv
anim
health
public
health
spinoff
ad
benefit
exampl
latter
may
includ
vaccin
hendra
nipah
viru
diseas
brucellosi
chlamydophila
feli
rift
valley
fever
venezuelan
equin
enceph
potenti
elimin
diseas
vaccin
employ
togeth
strategi
demonstr
brucellosi
us
terrestri
rabi
european
countri
compel
econom
concept
though
applic
select
case
cost
prevent
program
almost
alway
lower
emerg
respons
program
illustr
significantli
lower
cost
oral
wildlif
rabi
program
conting
action
control
epizoot
spread
recent
announc
higher
incid
lyme
diseas
previous
believ
lead
reassess
econom
prevent
strategi
diseas
includ
wildlif
vaccin
econom
repres
key
determin
develop
util
framework
ii
iii
vaccin
strategi
low
unit
cost
vaccin
alway
requir
econom
barrier
particularli
relev
consid
vaccin
develop
countri
posit
side
cost
develop
new
anim
vaccin
licensur
small
fraction
approxim
cost
typic
human
vaccin
latter
million
one
estim
often
far
higher
rel
lower
cost
shorter
timelin
develop
anim
vaccin
reflect
simpler
path
regulatori
approv
driven
significantli
lower
market
potenti
vaccin
despit
lower
cost
develop
new
veterinari
vaccin
high
middl
incom
countri
still
pay
higher
price
fix
cost
develop
paid
oversuppli
vaccin
compet
product
enter
market
redress
price
barrier
case
human
vaccin
strong
advocaci
new
approach
secur
vaccin
suppli
access
develop
countri
burden
infecti
diseas
greatest
part
strategi
emerg
market
manufactur
provid
access
low
unit
cost
vaccin
manufactur
veterinari
vaccin
could
play
substanti
role
public
health
strategi
anim
immun
inde
principl
appli
human
vaccin
could
extend
vaccin
anim
particularli
clear
rational
public
health
pull
potenti
expand
market
guarante
purchas
agreement
publicpriv
financ
develop
distribut
veterinari
vaccin
repres
tini
fraction
support
avail
human
developingworld
vaccin
focus
vaccin
livestock
mean
improv
anim
product
protein
suppli
rather
prevent
zoonot
diseas
given
public
health
impact
zoonot
diseas
describ
introduct
review
potenti
lower
cost
intervent
target
anim
vs
human
new
emphasi
public
health
improv
could
result
anim
immun
zoonot
diseas
merit
consider
occur
high
incid
poorli
control
includ
rabi
zoonot
leishmaniasi
brucellosi
rift
valley
fever
bovi
lyme
diseas
sever
enter
bacteri
infect
mention
regulatori
pathway
anim
vaccin
consider
simpler
human
vaccin
due
multipl
factor
includ
less
oner
requir
manufactur
control
veterinari
product
simpler
far
less
expens
clinic
trial
requir
market
approv
abil
challeng
anim
demonstr
vaccin
efficaci
well
establish
regulatori
mechan
condit
approv
allow
commerci
sale
still
gather
definit
data
requir
larg
statist
power
efficaci
field
trial
obtain
market
approv
case
human
vaccin
develop
veterinari
vaccin
consequ
far
faster
human
vaccin
exampl
west
nile
vaccin
hors
commerci
year
introduct
viru
us
wherea
first
phase
human
trial
west
nile
vaccin
complet
year
introduct
lower
cost
acceler
timefram
develop
anim
vaccin
repres
import
rational
novel
invest
public
health
particularli
develop
countri
justifi
invest
framework
ii
iii
vaccin
econom
incent
anim
immun
margin
public
health
benefit
goal
import
plan
vaccin
effect
studi
show
vaccin
anim
actual
reduc
human
diseas
preval
postul
greec
follow
vaccin
b
melitensi
demonstr
would
realli
drive
field
forward
thu
deploy
venezuelan
equin
enceph
vaccin
credit
curtail
human
epidem
control
studi
demonstr
effect
human
diseas
incid
actual
perform
inde
studi
confirm
attract
hypothesi
immun
domest
rumin
rift
valley
fever
africa
would
prevent
intermitt
outbreak
diseas
anim
human
leav
mosquito
reservoir
infect
intact
would
difficult
design
carri
discret
epidemiolog
hendra
viru
albeit
lowincid
diseas
present
uniqu
opportun
demonstr
effect
anim
immun
occurr
diseas
human
increas
problem
emerg
infect
major
result
spillov
anim
human
compel
reason
consid
novel
vaccin
intervent
collabor
veterinari
human
health
institut
develop
hendra
west
nile
vee
rift
valley
fever
vaccin
describ
review
serv
exampl
power
approach
potenti
target
vaccin
intervent
focus
anim
reservoir
intermedi
host
order
control
diseas
emerg
includ
avian
influenza
nipah
viru
diseas
possibl
middl
east
respiratori
syndrom
fund
agenc
industri
encourag
seek
integr
approach
prevent
zoonot
diseas
ultim
success
exampl
provid
review
e
coli
vaccin
cattl
reservoir
target
lyme
diseas
vaccin
field
mice
rift
valley
fever
vaccin
livestock
requir
sustain
effort
util
one
health
paradigm
